Preprint
Review
Version 1
Preserved in Portico This version is not peer-reviewed
Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis
,
,
,
,
*
Version 1
: Received: 31 May 2023 / Approved: 2 June 2023 / Online: 2 June 2023 (07:07:00 CEST)
A peer-reviewed article of this Preprint also exists.
Gumkowska-Sroka, O.; Kotyla, K.; Mojs, E.; Palka, K.; Kotyla, P. Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals 2023 , 16 , 1066.
Gumkowska-Sroka, O.; Kotyla, K.; Mojs, E.; Palka, K.; Kotyla, P. Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals 2023, 16, 1066.
Copy
Gumkowska-Sroka, O.; Kotyla, K.; Mojs, E.; Palka, K.; Kotyla, P. Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals 2023 , 16 , 1066.
Gumkowska-Sroka, O.; Kotyla, K.; Mojs, E.; Palka, K.; Kotyla, P. Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals 2023, 16, 1066.
Copy
CANCEL
COPY CITATION DETAILS
Abstract
Citation: Lastname, F.; Lastname, F.; Last-name, F. Title. Phar-maceuticals 2022, 15, x. https://doi.org/10.3390/xxxxx
Academic Editor: Firstname Lastname
Received: date
Accepted: date
Published: date
Publisher’s Note: MDPI stays neutral with regard to jurisdic-tional claims in pub-lished maps and insti-tutional affiliations.
Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons
1Olga Gumkowska-Sroka, 2Kacper Kotyla, 3Ewa Mojs, 2Klaudia Palka, 1,2*Przemysław Kotyla
1. Department of Rheumatology and Clinical Immunology Voivodeship Hospital No5 in Sosnowiec Medical University of Silesia Katowice, Poland
2. Department of Internal Medicine Rheumatology and Clinical Immunology Medical University of Silesia Katowice , Poland
3. 3. Department of Clinical Psychology, Poznan University of Medical Sciences Poznan, Poland
*Correspondence: Prof Przemysław Kotyla Department of Internal Medicine Rheumatology and Clinical Immunology Medical University of Silesia, Katowice, Poland-
Summary
Systemic sclerosis is a connective tissue disease of unknown origin and unpredictable course, with both cutaneous and internal organ manifestations. In spite of enormous progress in rheumatology and clinical immunology, the background of diseases is largely unknown and no specific therapy exists.
The therapeutic approach to the disease is aimed to treat and preserve the function of internal organs, and this approach is commonly referred to as an organ-based treatment. However, in modern times data from the other branches of medicine may help to treat disease-related complications, making it possible to find a group of drugs to be utilized in the treatment of the disease. In this review, we present possible therapeutic options aiming to stop the progression of fibrotic processes, restore aberrant immune response, stop improper signalling from proinflammatory cytokines, and halt the production of disease-related autoantibodies.
Keywords
Systemic sclerosis; treatment; Janus kinase inhibitors; fibrosis; anti-cytokine treatment
Subject
Medicine and Pharmacology, Immunology and Allergy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
* All users must log in before leaving a comment
what’s this?
Add a record of this review to Publons to track and showcase your reviewing expertise across the world’s journals.
×
